Seek Returns

A vs. CRL: Agilent vs. Charles River Laboratories Stock Comparison

How do Agilent (A) and Charles River Laboratories (CRL) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Agilent (A) and Charles River Laboratories (CRL) are both classified in the Life Sciences Tools & Services sub-industry within the broader Life Sciences Tools & Services industry, placing them in the closest GICS peer bucket.

Company profile comparison for Agilent (A) and Charles River Laboratories (CRL)
Profile ItemACRL
NameAgileThought, Inc. Class A Common StockCharles River Laboratories International, Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesLife Sciences Tools & Services
GICS Sub-IndustryLife Sciences Tools & ServicesLife Sciences Tools & Services
Market Capitalization49.28 billion USD16.17 billion USD
CurrencyUSDUSD
ExchangeNYSENYSE
Listing DateNovember 18, 1999June 23, 2000
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

A
CRL
GSPC
Loading price history…
Agilent (A) vs. Charles River Laboratories (CRL), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Agilent (A) and Charles River Laboratories (CRL). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Agilent (A) and Charles River Laboratories (CRL). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Agilent (A) and Charles River Laboratories (CRL)
MetricACRL
Total Return (1Y)22.92%110.83%
Total Return (3Y, Annualized)19.33%27.87%
Total Return (5Y, Annualized)3.03%-1.57%

Risk Profile

Drawdown History

A
CRL
GSPC
Loading price history…
Agilent (A) vs. Charles River Laboratories (CRL), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Agilent (A) and Charles River Laboratories (CRL). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Agilent (A) and Charles River Laboratories (CRL)
MetricACRL
Volatility (1Y, Annualized)33.10%47.81%
Beta (5Y)1.221.33
Max Drawdown (5Y)-38.09%-74.73%
Avg. Volume (3M)2.25M1.05M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
A and CRL are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Agilent (A) and Charles River Laboratories (CRL)
MetricACRL
Sharpe Ratio (1Y)0.562.23
Sortino Ratio (1Y)0.963.58

Profitability

ROE (TTM)

Agilent (A) at 20.97% sits in the top ROE quartile, while Charles River Laboratories (CRL) at 1.27% is closer to the peer norm — stronger capital efficiency for A.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.97%

Max
109.18%
A
20.97%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

CRL

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.27%

Max
109.18%
Q3
6.23%
CRL
1.27%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Agilent (A) vs. Charles River Laboratories (CRL): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Agilent (A) at 19.53% converts revenue to bottom-line profit above its industry’s benchmark range, while Charles River Laboratories (CRL) at 1.01% keeps roughly the typical share for its industry.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.53%

A
19.53%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

CRL

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.01%

Max
18.05%
Q3
4.78%
CRL
1.01%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Agilent (A) vs. Charles River Laboratories (CRL): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Agilent (A) at 25.56% and Charles River Laboratories (CRL) at 23.42% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.56%

Max
83.12%
A
25.56%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

CRL

Pharmaceuticals, Biotechnology & Life Sciences industry group

23.42%

Max
83.12%
CRL
23.42%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Agilent (A) vs. Charles River Laboratories (CRL): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Agilent (A) and Charles River Laboratories (CRL)
MetricACRL
ROE (TTM)20.97%1.27%
ROA (TTM)8.63%4.74%
Net Margin (TTM)19.53%1.01%
Operating Margin (TTM)25.56%23.42%
Gross Margin (TTM)53.65%35.10%

Growth

Revenue Growth

Agilent (A) at 6.73% is around its peer norm for revenue growth, while Charles River Laboratories (CRL) at -0.85% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Loading chart…
Agilent (A) vs. Charles River Laboratories (CRL): A comparison of their Revenue Growth across different time periods.

EPS Growth

Agilent (A) at 3.16% is around its peer norm for EPS growth, while Charles River Laboratories (CRL) at -1,555.00% falls below its industry range, a notably weak earnings reading.

Loading chart…
Agilent (A) vs. Charles River Laboratories (CRL): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Agilent (A) and Charles River Laboratories (CRL)
MetricACRL
Revenue Growth (YoY)6.73%-0.85%
Revenue Growth (3Y CAGR)0.48%0.33%
EPS Growth (YoY)3.16%-1,555.00%
EPS Growth (3Y CAGR)3.02%--

Financial Strength

Current Ratio (MRQ)

Both Agilent (A) at 2.05 and Charles River Laboratories (CRL) at 1.41 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.05

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
A
2.05
Min
0.10

CRL

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.41

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
CRL
1.41
Min
0.10
Loading chart…
Agilent (A) vs. Charles River Laboratories (CRL): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Agilent (A) at 0.56 carries an industry-typical debt-to-equity mix, while Charles River Laboratories (CRL) at 0.87 uses more debt funding than most peers.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.56

Max
1.42
Q3
0.65
A
0.56
Median
0.15
Q1
0.02
Min
0.00

CRL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.87

Max
1.42
CRL
0.87
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Agilent (A) vs. Charles River Laboratories (CRL): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Agilent (A) and Charles River Laboratories (CRL)
MetricACRL
Current Ratio (MRQ)2.051.41
Debt / Equity (MRQ)0.560.87
Net Debt / EBITDA1.152.92

Dividends

Dividend Yield (TTM)

Charles River Laboratories (CRL) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Agilent (A) reports a yield of 0.59%, ranking against industry peers normally.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.59%

A
0.59%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

CRL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

CRL
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Agilent (A) vs. Charles River Laboratories (CRL): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Charles River Laboratories (CRL) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Agilent (A) reports a payout of 19.98%, ranking against industry peers normally.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.98%

A
19.98%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

CRL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

CRL
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Agilent (A) vs. Charles River Laboratories (CRL): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Agilent (A) and Charles River Laboratories (CRL)
MetricACRL
Dividend Yield (TTM)0.59%0.00%
Dividend Payout Ratio (TTM)19.98%0.00%

Valuation

P/E Ratio (TTM)

Agilent (A) at 34.47 is near its industry’s usual P/E ratio, while Charles River Laboratories (CRL) at 366.87 sits above its peer range — an unusually expensive price for CRL’s trailing earnings.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

34.47

Max
85.34
Q3
43.46
A
34.47
Median
26.69
Q1
13.30
Min
0.07

CRL

Pharmaceuticals, Biotechnology & Life Sciences industry group

366.87

CRL
366.87
Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
Loading chart…
Agilent (A) vs. Charles River Laboratories (CRL): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Agilent (A) at 6.68 and Charles River Laboratories (CRL) at 4.07 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.68

Max
58.18
Q3
25.77
Median
7.30
A
6.68
Q1
3.01
Min
0.01

CRL

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.07

Max
58.18
Q3
25.77
Median
7.30
CRL
4.07
Q1
3.01
Min
0.01
Loading chart…
Agilent (A) vs. Charles River Laboratories (CRL): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Charles River Laboratories (CRL) at 5.01 is valued about in line with its industry on P/B ratio, while Agilent (A) at 6.69 carries an above-peer premium to book — A is pricier on assets.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.69

Max
13.53
A
6.69
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

CRL

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.01

Max
13.53
Q3
6.54
CRL
5.01
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Agilent (A) vs. Charles River Laboratories (CRL): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Agilent (A) and Charles River Laboratories (CRL)
MetricACRL
P/E Ratio (TTM)34.47366.87
P/S Ratio (TTM)6.684.07
P/B Ratio (MRQ)6.695.01
Free Cash Flow Yield (TTM)2.15%2.74%